You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

IMpassion031: Results from a Phase III study of neoadjuvant atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)

IMpassion031 is a global, phase III, multicentre, double-blind, randomised, placebo-controlled study in patients with high-risk primary invasive eTNBC evaluating the efficacy and safety of neoadjuvant atezolizumab or placebo with nab-paclitaxel followed by atezolizumab or placebo with dose-dense doxorubicin + cyclophosphamide. Here, we report the primary analysis of IMpassion031.

Request medical material

Would you like to receive this poster via email to view later?

Browse more content from this congress

View additional content from this congress. Use the filters to refine your search.
Disease Area
Molecule

Please validate reCAPTCHA.

Request received

Thank you! Please check your email to view the asset(s) you requested.
Continue browsing